Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia or Bipolar 1 Disorder Under the "New Drug Re-Examination"

NCT03386851 is registered in ClinicalTrials.gov with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03386851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03386851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia or Bipolar 1 Disorder Under the "New Drug Re-Examination"
Lead sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
December 13, 2016
Completion date
May 25, 2021
Enrollment
1,030 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar 1 disorder, schizophrenia